請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89207
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 方啓泰 | zh_TW |
dc.contributor.advisor | Chi-Tai Fang | en |
dc.contributor.author | 鄭容 | zh_TW |
dc.contributor.author | Jung Cheng | en |
dc.date.accessioned | 2023-09-05T16:06:30Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-05 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-08-01 | - |
dc.identifier.citation | 1. World Health Organization. HIV and AIDS. Available at https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed June 17, 2023.
2. Vergis EN, Mellors JW. Natural history of HIV-1 infection. Infect Dis Clin North Am. 2000;14(4):809-vi. 3. World Health Organization. The Global Health observatory. Summary of the global HIV epidemic, 2021. Available at https://www.who.int/data/gho/data/themes/hiv-aids. Accessed May 15, 2023. 4. Phanuphak N, Gulick RM. HIV treatment and prevention 2019: current standards of care. Curr Opin HIV AIDS. 2020;15(1):4-12. 5. Taiwan Centers for Disease Control, Ministry of Health and Welfare. HIV Month Report (April, 2023). Available at https://www.cdc.gov.tw/File/Get/iwe7Jm07Ty_8L0onTt9ozA. Accessed May 15, 2023. 6. Taiwan Centers for Disease Control, Ministry of Health and Welfare. HIV/AIDS Prevention and Control Manual, 2022. Available at https://www.cdc.gov.tw/InfectionReport/Info/SVtdjRgESOT_EwbAhjIJ4g?infoId=gsYxKbLQ8k4f1q2qlS55BQ. Accessed May 16, 2023. 7. Joint United Nations Program on HIV/AIDS. 90-90-90: Treatment for all, 2023. Available at https://www.unaids.org/en/resources/909090. Accessed May 29, 2023. 8. 蔡宜臻. End inequalities. End AIDS. End pandemics. Taiwan Epidemiol Bull. 2021;37:363. 9. Taiwan Centers for Disease Control, Ministry of Health and Welfare. Policy plan: 2030 AIDS Elimination Phase 1 Plan. Available at https://www.cdc.gov.tw/Category/Page/z-Lg5nEyp53uqCUGJ0t81A. Accessed June 17, 2023. 10. Taiwan AIDS Society. Guidelines for diagnosis and treatment of HIV/AIDS, 6th edition, 2020. Available at http://www.aids-care.org.tw/journal/treatment.php. Accessed May 8, 2023. 11. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860. 12. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505. 13. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med, 2016;375(9):830-909. 14. Sutton SS, Ahuja D, Magagnoli J. What is the effect of pill burden on adherence to HIV antiretroviral therapy?. JAAPA. 2016;29(11):16-17. 15. Solomon DA, Sax PE. Current state and limitations of daily oral therapy for treatment. Curr Opin HIV AIDS. 2015;10(4):219-225. 16. Sebaaly JC, Kelley D. HIV Clinical Updates: New Single-Tablet Regimens. Ann Pharmacother. 2019;53(1):82-94. 17. Beer L, Mattson CL, Bradley H, Shouse RL; Medical Monitoring Project. Trends in ART Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the United States, 2009-2013. J Acquir Immune Defic Syndr. 2017;76(1):e1-e6. 18. Oh KS, Seo GH, Choi HK, Han E. Effect of single tablet regimen on prescription trends for treatment-naïve patients with HIV/AIDS in Korea. Sci Rep. 2022;12(1):2031. 19. Tanaka H, Onoda T, Ishii T. Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care. Int J Environ Res Public Health. 2022;19(19):12130. 20. Taiwan Centers for Disease Control, Ministry of Health and Welfare. AIDS drug benefits, starting in June to keep pace with advanced countries. Available at https://www.cdc.gov.tw/Category/ListContent/TKG-8nvtp3Y1fHxeMxWJ1Q?uaid=aX0bX6S3Qmd89kfK9xSJKw. Accessed May 19, 2023. 21. European AIDS Clinical Society. Guidelines for treatment of people living with HIV version 11.1, October 2022. Available at https://www.eacsociety.org/guidelines/eacs-guidelines/. Accessed May 29, 2023. 22. Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63-84. 23. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475-490. 24. Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries. AIDS Res Ther. 2020;17(1):12. 25. Wang X, Schmerold L, Naito T. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan. J Infect Chemother. 2022 Nov;28(11):1464-1470. 26. Cotte L, Ferry T, Pugliese P, Valantin MA, Allavena C, Cabié A, et al. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PLoS One. 2017;12(2):e0170661. 27. Kapadia SN, Grant RR, German SB, Singh B, Davidow AL, Swaminathan S, et al. HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE Open Med. 2018 Dec 4;6:2050312118816919. 28. Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, et al. Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. PLoS One. 2011;6(6):e20713. 29. Costagliola D, Lacombe JM, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, et al. CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression. J Int AIDS Soc. 2014;17(4 Suppl 3):19481. 30. Raffi F, Le Moing V, Assuied A, Habak S, Spire B, Cazanave C, et al. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. J Antimicrob Chemother. 2017;72(1):240-245. 31. Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, et al. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. AIDS. 2018;32(17):2605-2614. 32. Mutoh Y, Nishijima T, Inaba Y, Tanaka N, Kikuchi Y, Gatanaga H, et al. Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy. Clin Infect Dis. 2018;67(6):927-933. 33. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441-446. 34. Palella FJ Jr, Armon C, Chmiel JS, Brooks JT, Hart R, Lichtenstein K, et al. CD4 cell count at initiation of ART, long-term likelihood of achieving CD4 >750 cells/mm3 and mortality risk. J Antimicrob Chemother. 2016;71(9):2654-2662. 35. Qadir MI. Hepatitis in AIDS patients. Rev Med Virol. 2018;28(1):10.1002/rmv.1956. 36. Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88(21-22):948-952. 37. Sarkar S, Brown TT. Diabetes in People with HIV. Curr Diab Rep. 2021;21(5):13. 38. De Anda-Duran I, Kimbrough AD, Bazzano LA. HIV and hypertension epidemiology. Curr Opin Cardiol. 2023;38(4):297-303. 39. Sekhar RV. Treatment of dyslipidemia in HIV. Curr Atheroscler Rep. 2015;17(4):493. 40. Wyatt CM. Kidney Disease and HIV Infection. Top Antivir Med. 2017;25(1):13-16. 41. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251-260. 42. Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr. 2009;51(2):163-174. 43. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807-1818. 44. Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43-52. 45. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials [published correction appears in Lancet. 2016 Apr 30;387(10030):1816]. Lancet. 2015;385(9987):2606-2615. 46. Taiwan Centers for Disease Control, Ministry of Health and Welfare. Guidelines for diagnosis and treatment of HIV/AIDS, 3rd edition, 2010. Available at https://www.cdc.gov.tw/InfectionReport/Info/3l4QiqDPV7_T_Cv9xjPvXA?infoId=Toh46XIzF6ij0jK0O0pT4w. Accessed June 26, 2023. 47. Taiwan Centers for Disease Control, Ministry of Health and Welfare. Guidelines for diagnosis and treatment of HIV/AIDS, 4th edition, 2013. Available at https://www.cdc.gov.tw/InfectionReport/Info/3l4QiqDPV7_T_Cv9xjPvXA?infoId=OLmFNrcN6tnw43Pbfx0PSw. Accessed June 26, 2023. 48. INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795-807. 49. TEMPRANO ANRS 12136 Study Group; Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808-822. 50. Taiwan AIDS Society. Guidelines for diagnosis and treatment of HIV/AIDS, 5th edition, 2018. Available at http://www.aids-care.org.tw/journal/treatment.php. Accessed May 8, 2023. 51. Wang CC, Shao CH, Li HJ, Sheng WH. Profiles and persistence of initial antiretroviral therapy among HIV infected patients in taiwan: A nationwide population-based cross-sectional study from 2011 to 2017. J Microbiol Immunol Infect. 2022;55(5):838-844. 52. Taiwan Centers for Disease Control, Ministry of Health and Welfare. AIDS Statistics, HIV Monthly Report, 104-12, 105-12, 106-12, 107-12, 108-12, 109-12 (December 2015, 2016, 2017, 2018, 2019, 2020). Available at https://www.cdc.gov.tw/Category/Page/rCV9N1rGUz9wNr8lggsh2Q. Accessed June 5, 2023. 53. Taiwan Ministry of Health Promotion Administration, Ministry of Health and Welfare. Report of Nutrition and Health Survey in Taiwan (2017-2020). Available at https://www.hpa.gov.tw/Pages/List.aspx?nodeid=3998. Accessed June 25, 2023. 54. Hanna DB, Hessol NA, Golub ET, Cocohoba JM, Cohen MH, Levine AM, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):587-96. 55. Burch LS, Smith CJ, Phillips AN, Johnson MA, Lampe FC. Socioeconomic status and response to antiretroviral therapy in high-income countries: a literature review. AIDS. 2016;30(8):1147-1162. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89207 | - |
dc.description.abstract | 背景及目的
高效能抗愛滋病毒治療(combination antiretroviral therapy, cART)有效改善了人類免疫缺乏病毒(human immunodeficiency virus, HIV)感染者和愛滋病(acquired immunodeficiency syndrome, AIDS)患者的預後,亦降低了 HIV 的傳播。由於過去多錠處方(multiple-tablet regimens, MTRs)的藥物負擔和副作用仍然造成 HIV 的治療困難,近年來服藥依從性及療效較高的單錠藥物(single-tablet regimens, STRs)已逐漸成為主流。台灣疾病管制署於1997年4月開始提供 cART ,並自2016年6月起將 STR 列為第一線藥物,然目前仍然缺乏 STR 對開始治療後 HIV 病毒載量抑制和 CD4 恢復時間影響的數據,且 STR 對亞洲族群耐受性影響的研究也有限。因此,本研究旨在以台灣真實世界數據比較 MTR 和 STR 治療對於 HIV/AIDS 患者的有效性和耐受性。 材料與方法 本研究為回溯性世代追蹤研究,以2013年至2018年在台大醫院初次使用 cART 的 HIV/AIDS 患者進行分析。研究結果包括 CD4 回復(達到 CD4 計數 ≥ 500 cells/μL)、病毒抑制(達到 HIV 病毒量 ≤ 50 copies/mL)和耐受性(換藥或停藥),並以 Cox 回歸模型比較 MTR 組和 STR 組並估計危險比。 結果 MTR 組共691名患者,STR 組共345名患者。CD4 回復的調整後危險比為 1.39(95% CI 1.07-1.81,P值=0.0150),病毒抑制為 1.52(95% CI 1.25-1.84,P值<.0001),耐受性的調整後危險比為 0.58(95% CI 0.49-0.69,P值<.0001)。 結論 相較於 MTR 組別, STR 組別的有效性和耐受性較高,CD4 較快回復及較快達到病毒抑制,且停藥或換藥率亦較低。 | zh_TW |
dc.description.abstract | Background.
Combination antiretroviral therapy (cART) is an effective way to improve the prognosis among human immunodeficiency virus (HIV) infected and acquired immunodeficiency syndrome (AIDS) patients and prevent the transmission of HIV. Due to treatment barriers caused by the pill burden and side effects of multiple-tablet regimens (MTRs) in the past, single-tablet regimens (STRs) have become mainstream with their higher adherence and effectiveness nowadays. Taiwan Centers for Disease Control started to provide cART for HIV patients in April 1997 and listed STRs as the recommended first-line treatment since June 2016. However, there is a lack of data on the real-world impact of STRs on the time to HIV viral load suppression and CD4 recovery after starting treatment and limited data on the impact of STRs on tolerability in Asian populations. Therefore, this study aims to compare the real-world effectiveness and tolerability of HIV/AIDS patients treated with MTRs and STRs through Taiwanese data. Materials and Methods. This retrospective cohort study analyzes the HIV/AIDS patients who initiated MTRs and STRs from 2013 to 2018 in the National Taiwan University Hospital. The study outcomes were CD4 recovery (reaching a CD4 count ≥ 500 cells/μL), viral suppression (reaching an HIV viral load ≤ 50 copies/mL), and tolerability (treatment interruption or switching to alternative treatments). The hazard ratios (HRs) of the STRs compared to the MTRs were estimated by Cox regression models. Results. There were 691 patients in the MTR group and 345 patients in the STR group. The adjusted HRs were 1.39 (95% CI 1.07-1.81, P-value=0.0150) for CD4 recovery, 1.52 (95% CI 1.25-1.84, P-value<.0001) for viral suppression, and 0.58 (95% CI 0.49-0.69, P-value<.0001) for tolerability. Conclusion. STRs were associated with faster CD4 recovery and viral suppression and a lower probability of treatment interruption or switching to alternative treatments, suggesting better effectiveness and tolerability compared to MTRs. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-05T16:06:30Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-05T16:06:30Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii Abstract iv Contents vi Abbreviations viii List of Figures ix List of Tables x Chapter 1 Introduction 1 1.1 HIV and AIDS 1 1.2 Epidemiology and prevention of HIV 1 1.3 Treatment for HIV: cART 2 1.4 Pill burden of cART and development from MTRs to STRs 2 1.5 Previous studies on MTRs and STRs 3 1.6 Research gap and study aim 5 Chapter 2 Materials and Methods 6 2.1 Study design 6 2.2 Ethical statement 6 2.3 Data source and study period 6 2.4 Inclusion and exclusion criteria 6 2.5 Study outcome 7 2.6 Definition of treatment length and treatment group 7 2.7 Follow-up period 8 2.8 Definition of covariates 8 2.9 Statistical analysis 9 2.9.1 Descriptive analysis 9 2.9.2 Survival analysis 10 2.9.3 Cox regression model 10 2.9.4 Sensitivity analysis 10 2.9.5 Statistical software 10 Chapter 3 Results 11 3.1 The study population of newly diagnosed HIV/AIDS patients who initiated cART 11 3.2 Treatment regimens of MTRs and STRs 12 3.3 Cumulative incidence for CD4 recovery and viral suppression between MTRs and STRs 12 3.4 Hazard ratios for CD4 recovery and viral suppression between MTRs and STRs 13 3.5 Survival for tolerability between MTRs and STRs 13 3.6 Hazard ratios for tolerability between MTRs and STRs 14 3.7 Sensitivity analysis 14 Chapter 4 Discussion 15 4.1 The improvement of STRs on effectiveness and tolerability compared to MTRs 15 4.2 The effect of initial CD4 count on CD4 recovery and viral suppression 16 4.3 Generalizability 17 4.4 Strengths and limitations 18 4.5 Conclusion 19 Acknowledgement 20 References 21 | - |
dc.language.iso | en | - |
dc.title | 比較 HIV 治療單錠處方與多錠處方的有效性及耐受性:回溯性世代追蹤研究 | zh_TW |
dc.title | Comparison of effectiveness and tolerability between single and multiple-tablet HIV treatment regimens: a retrospective cohort study | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 盤松青;施惟量;田中佐智子 | zh_TW |
dc.contributor.oralexamcommittee | Sung-Ching Pan;Wei-Liang Shih;Sachiko Tanaka | en |
dc.subject.keyword | 人類免疫缺乏病毒,愛滋病,高效能抗愛滋病毒治療,單錠處方,多錠處方, | zh_TW |
dc.subject.keyword | human immunodeficiency virus,acquired immunodeficiency syndrome,combination antiretroviral therapy,single-tablet regimen,multiple-tablet regimen, | en |
dc.relation.page | 43 | - |
dc.identifier.doi | 10.6342/NTU202302550 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-08-02 | - |
dc.contributor.author-college | 公共衛生學院 | - |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | - |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 目前未授權公開取用 | 1.26 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。